SPRF Chondrocyte Expansion Without Redifferentiation Drift
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for increasing chondrocyte proliferation, such as autologous chondrocyte implantation and platelet-rich plasma (PRP) therapies, face challenges in effectively promoting proliferation without differentiation and have inconsistent results, particularly for osteoarthritic chondrocytes, necessitating a more regulated and efficient approach.
Innovation Solution
The use of serum fraction of platelet-rich fibrin (SPRF) prepared from whole blood, centrifuged and processed to obtain a specific growth factor profile, is applied to increase chondrocyte proliferation in vitro and in vivo, without significant redifferentiation, using a method that includes centrifuging whole blood, forming a fibrin clot, and extracting the serum fraction to enhance chondrocyte proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If PRP is used to stimulate chondrocyte proliferation, then proliferation rate increases, but redifferentiation also occurs and results are inconsistent
Solution Approach 1:
The invention segments the blood components by using centrifugation to separate platelet-rich plasma from other blood components, then further processes it to create a standardized PRP product with controlled growth factor content. This segmentation allows selective utilization of beneficial components while eliminating variables that cause inconsistency in treatment results.
Solution Approach 2:
The invention applies parameter changes by standardizing the centrifugation conditions (speed, time, temperature) and establishing specific thresholds for growth factor concentrations (e.g., PDGF-BB ≥ 500 pg/mL, TGF-β1 ≥ 100 pg/mL). These parameter controls ensure consistent biological activity across different PRP preparations, resolving the reliability issue.
2Quantity of substance
If chondrocytes are expanded in vitro to increase cell numbers, then proliferation increases, but phenotypic stability is compromised
Solution Approach 1:
The invention uses PRP as an intermediary substance during in vitro chondrocyte expansion. PRP provides a natural growth factor environment that mediates cell proliferation while maintaining phenotypic stability, avoiding the need for traditional serum-based media that may cause dedifferentiation. The growth factors in PRP act as intermediaries to support both cell multiplication and phenotype preservation.
Solution Approach 2:
The invention changes the cultural medium parameters by replacing traditional fetal bovine serum with standardized PRP containing specific growth factor concentrations. This parameter change in the culture environment allows chondrocytes to proliferate while maintaining their differentiated state, as the PRP growth factors mimic physiological conditions.
3Adaptability or versatility
If different PRP preparations are used to treat cartilage defects, then treatment coverage increases, but comparability of results decreases
Solution Approach 1:
The invention creates a universal PRP standard that can be applied across different clinical scenarios (cartilage defects, osteoarthritis, sports injuries) while ensuring consistent results. The standardized formulation with defined growth factor thresholds provides multi-functionality across various indications while maintaining comparability through uniform preparation protocols.
Solution Approach 2:
The invention establishes specific parameter thresholds for PRP quality control (growth factor concentrations, cell counts, viscosity) that serve as universal benchmarks across all applications. These standardized parameters enable precise measurement and comparison of treatment outcomes regardless of the specific clinical indication, resolving the comparability issue.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
SPRF effectively increases the proliferation rate of chondrocytes, particularly dedifferentiated osteoarthritic chondrocytes, with reduced redifferentiation, and demonstrates enhanced proliferation compared to PRP, especially when derived from younger donors, providing a more controlled and effective treatment for cartilage repair.
Implementation Method 1
SPRF effectively increases the proliferation rate of chondrocytes, particularly dedifferentiated osteoarthritic chondrocytes
Implementation Method 2
centrifuged and processed to obtain a specific growth factor profile
Data Source
Figure 1A~1C
Figure 2
Figure 3A~3B
AI summary
The invention relates to a new method for increasing proliferation rate of chondrocytes. The present invention is applicable both in research and medicine among others to improve proliferation of chondrocytes without affecting their differentiation status.